ID   J2E
AC   CVCL_0355
SY   J2E-1
DR   MCCL; MCC:0000249
DR   Wikidata; Q54898464
RX   PubMed=1688637;
RX   PubMed=2847163;
RX   PubMed=8631947;
CC   Characteristics: Differentiates and synthesizes hemoglobin following exposure to EPO.
CC   Transformant: Recombinant retrovirus J2.
CC   Derived from site: In situ; Embryonic liver; UBERON=UBERON_0002107.
CC   Cell type: Erythroblast; CL=CL_0000765.
CC   Breed/subspecies: CBA.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Sex unspecified
AG   12FD
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 10
//
RX   PubMed=1688637;
RA   Klinken S.P., Nicola N.A.;
RT   "Evolution of a mutant J2E erythroid cell line which does not respond
RT   to erythropoietin.";
RL   Leukemia 4:24-28(1990).
//
RX   PubMed=2847163; DOI=10.1073/pnas.85.22.8506;
RA   Klinken S.P., Nicola N.A., Johnson G.R.;
RT   "In vitro-derived leukemic erythroid cell lines induced by a raf- and
RT   myc-containing retrovirus differentiate in response to
RT   erythropoietin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:8506-8510(1988).
//
RX   PubMed=8631947; DOI=10.1074/jbc.271.7.3453;
RA   Tilbrook P.A., Bittorf T., Busfield S.J., Chappell D., Klinken S.P.;
RT   "Disrupted signaling in a mutant J2E cell line that shows enhanced
RT   viability, but does not proliferate or differentiate, with
RT   erythropoietin.";
RL   J. Biol. Chem. 271:3453-3459(1996).
//